{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:34Z","timestamp":1793412154672,"version":"4.5.0"},"reference-count":219,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supp 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) infection has been a major global health concern, with a significant impact on public health. In recent years, there have been remarkable advancements in our understanding of HCV and the development of novel therapeutic agents. The Saudi Society for the Study of Liver Disease and Transplantation formed a working group to develop HCV practice guidelines in Saudi Arabia. The methodology used to create these guidelines involved a comprehensive review of available evidence, local data, and major international practice guidelines regarding HCV management. This updated guideline encompasses critical aspects of HCV care, including screening and diagnosis, assessing the severity of liver disease, and treatment strategies. The aim of this updated guideline is to assist healthcare providers in the management of HCV in Saudi Arabia. It summarizes the latest local studies on HCV epidemiology, significant changes in virus prevalence, and the importance of universal screening, particularly among high-risk populations. Moreover, it discusses the promising potential for HCV elimination as a public health threat by 2030, driven by effective treatment and comprehensive prevention strategies. This guideline also highlights evolving recommendations for advancing disease management, including the treatment of HCV patients with decompensated cirrhosis, treatment of those who have previously failed treatment with the newer medications, management in the context of liver transplantation and hepatocellular carcinoma, and treatment for special populations.<\/jats:p>","DOI":"10.4103\/sjg.sjg_333_23","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T03:00:15Z","timestamp":1704250815000},"page":"S1-S42","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024"],"prefix":"10.4103","volume":"30","author":[{"given":"Abdullah S.","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Hepatology Section, Hepatobiliary Sciences and Organs Transplant Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleema A.","family":"Alserehi","sequence":"additional","affiliation":[{"name":"General Directorate of Communicable Diseases, Ministry of Health, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Babatin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Alswat","sequence":"additional","affiliation":[{"name":"Liver Disease Research Center, and Riyadh, Saudi Arabia"},{"name":"College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, King Fahd Military Complex, Dhahran, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"AlQutub","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Abaalkhail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"},{"name":"College of Medicine, Al Faisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Altraif","sequence":"additional","affiliation":[{"name":"Hepatology Section, Hepatobiliary Sciences and Organs Transplant Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faleh Z.","family":"Alfaleh","sequence":"additional","affiliation":[{"name":"Liver Disease Research Center, and Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal M.","family":"Sanai","sequence":"additional","affiliation":[{"name":"Liver Disease Research Center, and Riyadh, Saudi Arabia"},{"name":"Gastroenterology Section, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/1319-3767.103425","article-title":"Epidemiology of viral hepatitis in Saudi Arabia:Are we off the hook?","volume":"18","author":"Abdo","year":"2012","journal-title":"Saudi J Gastroenterol"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/jech.2009.093302","article-title":"Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors?","volume":"64","author":"Alswaidi","year":"2010","journal-title":"J Epidemiol Community Health"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/1319-3767.187609","article-title":"Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift","volume":"22","author":"Aljumah","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5144\/0256-4947.2013.10","article-title":"HCV genotypes among 1013 Saudi nationals:A multicenter study","volume":"33","author":"Al Traif","year":"2013","journal-title":"Ann Saudi Med"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","article-title":"Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays:An analysis of the literature","volume":"8","author":"Colin","year":"2001","journal-title":"J Viral Hepat"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijid.2005.07.008","article-title":"Distribution of hepatitis C virus genotypes in the Middle East","volume":"10","author":"Ramia","year":"2006","journal-title":"Int J Infect Dis"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cmi.2016.01.009","article-title":"Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care","volume":"22","author":"Chevaliez","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cgh.2006.02.002","article-title":"Chronic hepatitis C in patients with persistently normal alanine transaminase levels","volume":"4","author":"Shiffman","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S2468-1253(18)30271-1","article-title":"HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals:Retrospective screening and diagnostic cohort studies","volume":"3","author":"van Tilborg","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jfma.2020.08.019","article-title":"The non-invasive assessment of hepatic fibrosis","volume":"120","author":"Gheorghe","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/1319-3767.33470","article-title":"Fibroscan\u00ae:A noninvasive test of liver fibrosis assessment","volume":"13","author":"Al-Ghamdi","year":"2007","journal-title":"Saudi J Gastroenterol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis:A meta-analysis","volume":"134","author":"Friedrich\u2013Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/cid\/ciz949","article-title":"Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany:Current incidence rates, compared with rates during the interferon era","volume":"71","author":"Ingiliz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/07853890.2021.2012589","article-title":"Drug-induced liver injury by glecaprevir\/pibrentasvir treatment for chronic hepatitis C infection:A systematic review and meta-analysis","volume":"54","author":"Hung","year":"2022","journal-title":"Ann Med"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/diagnostics12051255","article-title":"Diagnostic accuracy of point-of-care HCV viral load assays for hcv diagnosis:A systematic review and meta-analysis","volume":"12","author":"Tang","year":"2022","journal-title":"Diagnostics"},{"key":"R23-20240829","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/1319-3767.153810","article-title":"SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection","volume":"21","author":"Alghamdi","year":"2015","journal-title":"Saudi J Gastroenterol"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.aohep.2020.09.012","article-title":"Real-world effectiveness of direct-acting antiviral regimens against hepatitis C virus (HCV) genotype 3 infection:A systematic review and meta-analysis","volume":"23","author":"Zhuang","year":"2021","journal-title":"Ann Hepatol"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cgh.2014.12.014","article-title":"Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C:A United States multicenter study","volume":"13","author":"Afdhal","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection:A systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"R31-20240829","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.26741","article-title":"Fibrosis progression in human immunodeficiency virus\/hepatitis C virus coinfected adults:Prospective analysis of 435 liver biopsy pairs","volume":"59","author":"Konerman","year":"2014","journal-title":"Hepatology"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1440-1746.2006.04547.x","article-title":"Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients","volume":"22","author":"Lee","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case\u2013control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"Br J Cancer"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus\u2013coinfected patients","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"key":"R35-20240829","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/hep.24308","article-title":"Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection","volume":"53","author":"Nguyen","year":"2011","journal-title":"Hepatology"},{"key":"R36-20240829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:A systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"R37-20240829","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.29135","article-title":"Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals","volume":"66","author":"Belperio","year":"2017","journal-title":"Hepatology"},{"key":"R38-20240829","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"R39-20240829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/sjg.sjg_539_20","article-title":"SASLT practice guidelines for the management of Hepatitis B virus\u2013An update","volume":"27","author":"Abaalkhail","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"R40-20240829","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"R41-20240829","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/jcm9020563","article-title":"The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus:A word of caution after the initial enthusiasm","volume":"9","author":"Ribaldone","year":"2020","journal-title":"J Clin Med"},{"key":"R42-20240829","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R43-20240829","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"R44-20240829","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C:Final update of the series*","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"R45-20240829","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cgh.2018.07.003","article-title":"Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection","volume":"17","author":"Flamm","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R46-20240829","doi-asserted-by":"crossref","first-page":"1170039","DOI":"10.3389\/fphar.2023.1170039","article-title":"Proarrhythmia associated with antiarrhythmic drugs:A comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R47-20240829","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection:2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"R48-20240829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"R49-20240829","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/tera.1420170117","article-title":"Teratogenic effects of ribavirin on hamster and rat embryos","volume":"17","author":"Ferm","year":"1978","journal-title":"Teratology"},{"key":"R50-20240829","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"R52-20240829","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"R53-20240829","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in Phase 2 and 3 clinical trials","volume":"28","author":"Gane","year":"2021","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"R54-20240829","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.SJG_477_20","article-title":"Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma","volume":"26","author":"Alqahtani","year":"2020","journal-title":"Saudi J Gastroenterol"},{"key":"R55-20240829","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"R56-20240829","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2013renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"R57-20240829","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J Hepatol"},{"key":"R58-20240829","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus:From bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"key":"R59-20240829","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C:A systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R60-20240829","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir\u2013pibrentasvir to treat chronic hepatitis C virus infection in Asia:Two multicentre, phase 3 studies\u2014A randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R61-20240829","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus:Prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"R62-20240829","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis","volume":"53","author":"Chayama","year":"2018","journal-title":"J Gastroenterol"},{"key":"R63-20240829","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00535-019-01569-7","article-title":"Integrated analysis of 8-week glecaprevir\/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection","volume":"54","author":"Naganuma","year":"2019","journal-title":"J Gastroenterol"},{"key":"R64-20240829","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection:Data from the German hepatitis C-registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R65-20240829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"R66-20240829","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1):A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R67-20240829","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0168-8278(17)30467-1","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1:The EXPEDITION-2 study","volume":"1","author":"Rockstroh","year":"2017","journal-title":"J Hepatol"},{"key":"R68-20240829","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis:The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"R69-20240829","first-page":"1","article-title":"Real-world effectiveness of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve, compensated cirrhotic HCV patients","author":"Reau","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R70-20240829","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1007\/s12325-022-02158-6","article-title":"Safety and effectiveness using 8 weeks of glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis:The CREST study","volume":"39","author":"Cornberg","year":"2022","journal-title":"Adv Ther"},{"key":"R71-20240829","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"R72-20240829","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"key":"R73-20240829","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment:Analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"R74-20240829","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/velpatasvir for hepatitis C virus infection:Real-world effectiveness and safety from a nationwide registry in Taiwan","volume":"11","author":"Cheng","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R75-20240829","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/v14112493","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as a highly effective treatment and elimination tool in people with hepatitis C infection experiencing mental health disorders","volume":"14","author":"Wedemeyer","year":"2022","journal-title":"Viruses"},{"key":"R76-20240829","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciw163","article-title":"12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study):Efficacy and safety by HIV combination antiretroviral regimens","volume":"62","author":"Luetkemeyer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R77-20240829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R78-20240829","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"R79-20240829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J Hepatol"},{"key":"R80-20240829","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cmi.2018.06.007","article-title":"Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1:A randomized clinical trial","volume":"25","author":"Pott-Junior","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R81-20240829","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatology"},{"key":"R82-20240829","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"R83-20240829","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/liv.13069","article-title":"The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin","volume":"36","author":"Mangia","year":"2016","journal-title":"Liver Int"},{"key":"R84-20240829","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jvh.13321","article-title":"Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection:Real-life experience from the HEPATHER ANRS CO22 cohort","volume":"27","author":"de L\u00e9dinghen","year":"2020","journal-title":"J Viral Hepat"},{"key":"R85-20240829","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J Hepatol"},{"key":"R86-20240829","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jfma.2018.09.016","article-title":"Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan","volume":"118","author":"Cheng","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"Suppl 1","key":"R87-20240829","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0618-8278(19)30231-2","article-title":"Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England:high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis","volume":"70","author":"Drysdale","year":"2019","journal-title":"J Hepatol"},{"key":"R88-20240829","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia:A single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R89-20240829","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jvh.13239","article-title":"Eight weeks of sofosbuvir\/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2\/3) fibrosis","volume":"27","author":"Boyle","year":"2020","journal-title":"J Viral Hepat"},{"key":"R90-20240829","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/apt.15780","article-title":"English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed","volume":"52","author":"Drysdale","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R91-20240829","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4254\/wjh.v14.i6.1248","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis:A meta-analysis","volume":"14","author":"Loo","year":"2022","journal-title":"World J Hepatol"},{"key":"R92-20240829","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"R93-20240829","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"Von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R94-20240829","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30326-4","article-title":"ENDURANCE-3:Safety and efficacy of glecaprevir\/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-na\u00efve HCV genotype 3-infected patients without cirrhosis","volume":"66","author":"Foster","year":"2017","journal-title":"J Hepatol"},{"key":"R95-20240829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jvh.13038","article-title":"Glecaprevir\/pibrentasvir in patients with chronic HCV genotype 3 infection:An integrated phase 2\/3 analysis","volume":"26","author":"Flamm","year":"2019","journal-title":"J Viral Hepat"},{"key":"R96-20240829","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"R97-20240829","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience:A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"R98-20240829","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(19)40035-8","article-title":"956\u2013Safety and Efficacy of Glecaprevir\/Pibrentasvir for the Treatment of Hcv Genotype 1-6:Results of the Hcv-Target Study","volume":"156","author":"Sterling","year":"2019","journal-title":"Gastroenterology"},{"key":"R99-20240829","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12072-023-10506-z","article-title":"Effectiveness and safety of 8-week glecaprevir\/pibrentasvir in HCV treatment-na\u00efve patients with compensated cirrhosis:Real-world experience from Taiwan nationwide HCV registry","volume":"17","author":"Chang","year":"2023","journal-title":"Hepatol Int"},{"key":"R100-20240829","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection:A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"key":"R101-20240829","first-page":"137","article-title":"Effectiveness and safety of daclatasvir\/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice","volume":"32","author":"Margusino-Frami\u00f1\u00e1n","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"R102-20240829","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:A randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"R103-20240829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3851\/IMP3278","article-title":"Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis:A Phase III study (ALLY-3C)","volume":"24","author":"Poordad","year":"2019","journal-title":"Antivir Ther"},{"key":"R104-20240829","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.12669\/pjms.37.7.4627","article-title":"Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C:An experience of tertiary care hospital in Karachi","volume":"37","author":"Butt","year":"2021","journal-title":"Pak J Med Sci"},{"key":"R105-20240829","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5009\/gnl18269","article-title":"High efficacy and safety of flat-dose ribavirin plus sofosbuvir\/daclatasvir in genotype 3 cirrhotic patients","volume":"14","author":"Pellicelli","year":"2020","journal-title":"Gut and Liver"},{"key":"R106-20240829","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.aohep.2018.09.005","article-title":"Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis:A real-life study","volume":"18","author":"Lionetti","year":"2019","journal-title":"Ann Hepatol"},{"key":"R107-20240829","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R108-20240829","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/liv.14937","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis:Safety and effectiveness data from the German Hepatitis C-Registry","volume":"41","author":"Klinker","year":"2021","journal-title":"Liver Int"},{"key":"R109-20240829","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00398-8","article-title":"Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3):A single-arm trial","volume":"7","author":"Kateera","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R110-20240829","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"R111-20240829","doi-asserted-by":"crossref","first-page":"S619","DOI":"10.1016\/S0168-8278(15)30975-2","article-title":"P0772:Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease:Interim results of a multicenter compassionate use program","author":"Welzel","year":"2015","journal-title":"J Hepatol"},{"key":"R112-20240829","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MCG.0000000000000896","article-title":"Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitis C genotype 4 infection","volume":"52","author":"Babatin","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"R113-20240829","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1016\/S0168-8278(16)01471-9","article-title":"Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5 and 6","volume":"2","author":"Hezode","year":"2016","journal-title":"J Hepatol"},{"key":"R114-20240829","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajg.2021.06.001","article-title":"Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection:A real-world single-center experience","volume":"22","author":"Naguib","year":"2021","journal-title":"Arab J Gastroenterol"},{"key":"R115-20240829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5, 6):An open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R116-20240829","first-page":"1449A","article-title":"Preliminary efficacy and safety of 8-week glecaprevir\/pibrentasvir in patients with HCV genotype 1\u20136 infection and compensated cirrhosis:The Expedition-8 Study","volume":"68","author":"Brown","year":"2018","journal-title":"Hepatology"},{"key":"R117-20240829","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/liv.14535","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with HCV genotype 5\/6:An integrated analysis of phase 2\/3 studies","volume":"40","author":"Yao","year":"2020","journal-title":"Liver Int"},{"key":"R118-20240829","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jfma.2022.04.020","article-title":"Real-world effectiveness and safety of sofosbuvir\/velpatasvir and glecaprevir\/pibrentasvir for genotype 6 chronic hepatitis C","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"R119-20240829","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jvh.13033","article-title":"Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China:Real-world experience of a retrospective study","volume":"26","author":"Wu","year":"2019","journal-title":"J Viral Hepat"},{"key":"R120-20240829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/apt.15043","article-title":"Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir","volume":"49","author":"Nguyen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R122-20240829","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.13311","article-title":"High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia","volume":"27","author":"Zhang","year":"2020","journal-title":"J Viral Hepat"},{"key":"R123-20240829","doi-asserted-by":"crossref","first-page":"e0233446","DOI":"10.1371\/journal.pone.0233446","article-title":"Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients:Real-world experience in Vietnam","volume":"15","author":"Nguyen","year":"2020","journal-title":"PLoS One"},{"key":"R124-20240829","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.15100","article-title":"Systematic review:Epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection","volume":"49","author":"Mettikanont","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R125-20240829","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication:A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"R126-20240829","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"key":"R127-20240829","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jvh.12877","article-title":"The optimal timing of hepatitis C therapy in liver transplant-eligible patients:Cost-effectiveness analysis of new opportunities","volume":"25","author":"Cortesi","year":"2018","journal-title":"J Viral Hepat"},{"key":"R128-20240829","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12879-022-07076-0","article-title":"Clinical outcomes after treatment with direct antiviral agents:Beyond the virological response in patients with previous HCV-related decompensated cirrhosis","volume":"22","author":"Pageaux","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R129-20240829","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R130-20240829","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s12072-023-10547-4","article-title":"Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis:A REAL-C study","volume":"17","author":"Wong","year":"2023","journal-title":"Hepatol Int"},{"key":"R131-20240829","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"R132-20240829","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3390\/v15102026","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir plus ribavirin in patients with hepatitis C virus-related decompensated cirrhosis","volume":"15","author":"Flamm","year":"2023","journal-title":"Viruses"},{"key":"R133-20240829","first-page":"728","article-title":"Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV:Interim results of a multicenter compassionate use program","volume":"S623","author":"Rockstroh","year":"2015","journal-title":"J Hepatol"},{"key":"R134-20240829","first-page":"e3296","article-title":"D\u00e9j\u00e0vu All Over Again:Retreatment of HCV Direct Acting Antivirals Failures\u2014Same Satisfactory Results, Same Unanswered Questions","author":"Sulkowski","year":"2021","journal-title":"Oxford University Press US"},{"key":"R135-20240829","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"R136-20240829","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","article-title":"Deferred treatment with sofosbuvir\u2013velpatasvir\u2013voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor:An open-label substudy of POLARIS-1","volume":"3","author":"Bourli\u00e8re","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R137-20240829","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world:A systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R138-20240829","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2023.04.011","article-title":"A randomized-controlled trial of SOF\/VEL\/VOX with or without ribavirin for retreatment of chronic hepatitis C","volume":"79","author":"El-Kassas","year":"2023","journal-title":"J Hepatol"},{"key":"R139-20240829","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"R140-20240829","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"R141-20240829","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J Hepatol"},{"key":"R142-20240829","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R143-20240829","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"R144-20240829","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1872-034X.2011.00781.x","article-title":"Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation","volume":"41","author":"Satapathy","year":"2011","journal-title":"Hepatol Res"},{"key":"R145-20240829","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hep.29918","article-title":"12 weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation","volume":"68","author":"Houssel-Debry","year":"2018","journal-title":"Hepatology"},{"key":"R146-20240829","doi-asserted-by":"crossref","first-page":"e980","DOI":"10.1002\/hsr2.980","article-title":"Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir\/ledipasvir in genotype 4 hepatitis C virus:A prospective comparison with historical control","volume":"6","author":"Joharji","year":"2023","journal-title":"Health Sci Rep"},{"key":"R147-20240829","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/lt.24614","article-title":"Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients","volume":"22","author":"Kwok","year":"2016","journal-title":"Liver Transpl"},{"key":"R148-20240829","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"R149-20240829","first-page":"214","article-title":"Hepatitis C virus and liver transplantation","volume":"13","author":"Bhamidimarri","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R150-20240829","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"key":"R151-20240829","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1189\/jlb.1107774","article-title":"Immune-mediated dormancy:An equilibrium with cancer","volume":"84","author":"Teng","year":"2008","journal-title":"J Leucocyte Biol"},{"key":"R152-20240829","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment:A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"R153-20240829","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero","year":"2019","journal-title":"Liver Int"},{"key":"R154-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis:A meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"R155-20240829","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/apt.15598","article-title":"Systematic review with meta-analysis:Effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma","volume":"51","author":"He","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R156-20240829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/v15010137","article-title":"Patients treated for HCV infection and listed for liver transplantation in a French multicenter study:What happens at five years?","volume":"15","author":"Meunier","year":"2022","journal-title":"Viruses"},{"key":"R157-20240829","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J Hepatol"},{"key":"R158-20240829","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals?A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R159-20240829","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"Ogawa","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R160-20240829","first-page":"293","article-title":"Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C:A meta-analysis","volume":"33","author":"Lui","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"R161-20240829","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/jcm10081694","article-title":"Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis","volume":"10","author":"Frazzoni","year":"2021","journal-title":"J Clin Med"},{"key":"R162-20240829","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"key":"R163-20240829","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents:The DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"key":"R164-20240829","first-page":"442","article-title":"Hepatitis C in dialysis patients","volume":"14","author":"Huraib","year":"2003","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R165-20240829","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.29505","article-title":"Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD","volume":"67","author":"Park","year":"2018","journal-title":"Hepatology"},{"key":"R166-20240829","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cgh.2022.01.050","article-title":"Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R167-20240829","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus\u2013associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"R168-20240829","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1681\/ASN.2006070736","article-title":"Hepatitis C virus and death risk in hemodialysis patients","volume":"18","author":"Kalantar-Zadeh","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R169-20240829","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int"},{"key":"R170-20240829","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"R171-20240829","doi-asserted-by":"crossref","first-page":"S738","DOI":"10.1016\/S0168-8278(17)31967-0","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1\u20136 and chronic kidney disease:An integrated analysis","volume":"1","author":"Pol","year":"2017","journal-title":"J Hepatol"},{"key":"R172-20240829","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"R173-20240829","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","article-title":"Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment:a multicentre, phase 2b, non-randomised, open-label study","volume":"5","author":"Lawitz","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R174-20240829","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","article-title":"Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment:A multicentre, phase 2b, non-randomised, open-label study","volume":"5","author":"Lawitz","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R175-20240829","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"R176-20240829","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep4.1035","article-title":"Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction","volume":"1","author":"Cox-North","year":"2017","journal-title":"Hepatol Commun"},{"key":"R177-20240829","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"R178-20240829","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","article-title":"Impact of Sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function:A large Cohort Study from the Nationwide HCV Registry Program (TACR)","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R179-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease:A systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"R180-20240829","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2018.05.039","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in genotype 1\u20134 HCV-infected liver transplant recipients","volume":"69","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"R181-20240829","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17425255.2017.1359254","article-title":"Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C","volume":"13","author":"Soriano","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R182-20240829","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study):A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"The Lancet"},{"key":"R183-20240829","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","article-title":"DAA-based antiviral treatment of patients with chronic hepatitis C in the pre-and postkidney transplantation setting","volume":"29","author":"Beinhardt","year":"2016","journal-title":"Transpl Int"},{"issue":"S1","key":"R184-20240829","article-title":"Combination\/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study):an interim analysis","volume":"66","author":"Han","year":"2017","journal-title":"Hepatology."},{"key":"R185-20240829","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"key":"R186-20240829","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/ajt.15583","article-title":"Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients:A unique complication in the DAA era","volume":"20","author":"Kapila","year":"2020","journal-title":"Am J Transplant"},{"key":"R187-20240829","first-page":"1105","article-title":"Transplanting HCV-infected kidneys into uninfected recipients","volume":"377","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R188-20240829","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.ajkd.2022.12.019","article-title":"Kidney transplantation from hepatitis C virus\u2013infected donors to uninfected recipients:A systematic review for the KDIGO 2022 hepatitis C Clinical Practice Guideline Update","volume":"82","author":"Gordon","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R189-20240829","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/IDR.S270355","article-title":"HIV in the Kingdom of Saudi Arabia:Can we change the way we deal with co-infections","volume":"14","author":"Al-Mozaini","year":"2021","journal-title":"Infect Drug Resist"},{"key":"R190-20240829","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5144\/0256-4947.2014.207","article-title":"Viral hepatitis B and C in HIV-infected patients in Saudi Arabia","volume":"34","author":"Alhuraiji","year":"2014","journal-title":"Ann Saudi Med"},{"key":"R191-20240829","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/cid\/cis1206","article-title":"Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection","volume":"56","author":"Fierer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R192-20240829","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus\/hepatitis C virus","volume":"50","author":"Mac\u00edas","year":"2009","journal-title":"Hepatology"},{"key":"R193-20240829","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1\u2013coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R194-20240829","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1:The EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R195-20240829","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jhep.2019.05.021","article-title":"A pilot study of safety and efficacy of HCV retreatment with sofosbuvir\/velpatasvir\/voxilaprevir in patients with or without HIV (RESOLVE STUDY)","volume":"71","author":"Wilson","year":"2019","journal-title":"J Hepatol"},{"key":"R196-20240829","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/jvh.13844","article-title":"Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy","volume":"30","author":"De","year":"2023","journal-title":"J Viral Hepat"},{"key":"R197-20240829","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/apt.14647","article-title":"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection","volume":"47","author":"Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R198-20240829","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkad278","article-title":"Response to glecaprevir\/pibrentasvir in HIV\/HCV-coinfected patients in clinical practice","volume":"78","author":"Gonzalez-Serna","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R199-20240829","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmi.2016.12.003","article-title":"Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus","volume":"23","author":"Puoti","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R200-20240829","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.26400","article-title":"Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients","volume":"58","author":"Tyson","year":"2013","journal-title":"Hepatology"},{"key":"R201-20240829","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3109\/00365520903329585","article-title":"Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin","volume":"44","author":"Potthoff","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R202-20240829","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","volume":"15","author":"Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R203-20240829","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C:A systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R204-20240829","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus:A review of cases reported to the US Food and Drug Administration Adverse Event Reporting System","volume":"166","author":"Bersoff-Matcha","year":"2017","journal-title":"Ann Intern Med"},{"key":"R205-20240829","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R206-20240829","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14740\/gr971w","article-title":"Prevalence of hepatitis B reactivation among Chinese individuals with chronic hepatitis C treated with pan-oral direct-acting antivirals","volume":"11","author":"Lee","year":"2018","journal-title":"Gastroenterol Res"},{"key":"R207-20240829","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"key":"R208-20240829","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C?A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"R209-20240829","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1093\/cid\/ciac680","article-title":"Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study)","volume":"76","author":"Monin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R210-20240829","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection","volume":"75","author":"Matthews","year":"2021","journal-title":"J Hepatol"},{"key":"R211-20240829","doi-asserted-by":"crossref","first-page":"100650","DOI":"10.1016\/j.jhepr.2022.100650","article-title":"Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C:The HepNet acute HCV-V study","volume":"5","author":"Maasoumy","year":"2023","journal-title":"JHEP Rep"},{"key":"R212-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello","year":"2020","journal-title":"Hepatology"},{"key":"R213-20240829","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/j.jhepr.2023.100867","article-title":"Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection:The TARGET3D study","volume":"5","author":"Martinello","year":"2023","journal-title":"JHEP Rep"},{"key":"R214-20240829","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/ndt\/gfaa187","article-title":"Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir","volume":"36","author":"Goel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R215-20240829","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ejh.12086","article-title":"Natural history of hepatitis C in thalassemia major:A long-term prospective study","volume":"90","author":"Lai","year":"2013","journal-title":"Eur J Haematol"},{"key":"R216-20240829","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1002\/ajh.25339","article-title":"Sofosbuvir\/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia","volume":"94","author":"Sharara","year":"2019","journal-title":"Am J Hematol"},{"key":"R217-20240829","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/liv.14337","article-title":"High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection:A multicenter study","volume":"40","author":"Mancuso","year":"2020","journal-title":"Liver Int"},{"key":"R218-20240829","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jiph.2019.06.001","article-title":"National screening programs in Saudi Arabia:Overview, outcomes, and effectiveness","volume":"12","author":"Gosadi","year":"2019","journal-title":"J Infection Public Health"},{"key":"R219-20240829","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2022.05.016","article-title":"Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission","volume":"77","author":"Kushner","year":"2022","journal-title":"J Hepatol"},{"key":"R220-20240829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinre.2016.07.004","article-title":"Hepatitis C infection and intrahepatic cholestasis of pregnancy:A systematic review and meta-analysis","volume":"41","author":"Wijarnpreecha","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R221-20240829","first-page":"134","article-title":"Safety and efficacy of treatment for chronic hepatitis C during pregnancy:A prospective observational study in Srinagar, India","volume":"22","author":"Yattoo","year":"2023","journal-title":"Clin Liver Dis"},{"key":"R222-20240829","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection:A phase 1 pharmacokinetic study","volume":"1","author":"Chappell","year":"2020","journal-title":"Lancet Microbe"},{"key":"R223-20240829","first-page":"18","article-title":"Safety, tolerability, and outcomes of sofosbuvir\/velpatasvir in treatment of chronic hepatitis C virus during pregnancy:Interim results from the STORC study","volume":"78","author":"Chappell","year":"2023","journal-title":"Hepatology"},{"key":"R224-20240829","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(95)90277-5","article-title":"Mother-to-infant transmission of hepatitis C virus","volume":"345","author":"Zanetti","year":"1995","journal-title":"Lancet"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_333_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:58:13Z","timestamp":1787763493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_333_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":219,"journal-issue":{"issue":"Supp 1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_333_23","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-09-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}